IVD Trends to Watch: Coagulation Market to Reach $3.2 Billion and 920 Million Procedures in 2029
The global market for in vitro diagnostic (IVD) laboratory coagulation products is forecast to grow steadily, driven by the increasing volume of surgical procedures, the widespread adoption of enhanced post-surgical monitoring activities, and increasing applications in surgical, inpatient, and emergency care settings. According to the October 2024 market report IVD Test Procedure Volumes, 2024-2029 by Kalorama Information, the global volume of coagulation testing procedures will total 801,497,869 by the end of 2024. This number will exceed 920,025,000 procedures and coincide with sales exceeding $3.2 billion in 2029.
This growth is underpinned by the expanding availability of blood thinners, such as Apixaban (Eliquis), Dabigatran (Pradaxa), Edoxaban (Savaysa), and Rivaroxaban (Xarelto), which require less frequent monitoring. Hospitals will continue to be the largest end-use segment for laboratory-based coagulation tests due to the elevated risk of thrombolytic complications faced by many patients.
Coagulation tests are essential for diagnosing and monitoring various bleeding disorders and evaluating the effectiveness of blood-related therapies, such as anticoagulant agents like heparin and warfarin. Utilizing a combination of hematological, immunological, and chromogenic techniques, these tests provide detailed insights into blood clotting and formation processes.
“Leading suppliers of laboratory IVD coagulation products, such as Abbott Diagnostics, Diagnostica Stago, Instrumentation Laboratory, Siemens Healthineers, and Sysmex, continue to innovate and introduce new products to the market. For instance, there exist relatively recent automated blood coagulation analyzers that offer advanced features and improved efficiency, helping laboratories streamline their workflows and improve patient care.”
Geographically, North America leads in the number of laboratory coagulation procedures conducted globally, followed closely by Western Europe. The Asia Pacific region and other areas also contribute significantly to the global volume (see chart below). While North America performs more INR/PT and PTT tests, Western Europe conducts a higher volume of specialized coagulation factor procedures, reflecting regional differences in medical practices and patient needs.
Among the various types of coagulation tests, the prothrombin time (PT) assay is the most widely performed. This test evaluates the adequacy of the extrinsic system and common pathway involved in the blood clotting process. It is regularly administered to patients taking anticoagulants like warfarin to monitor their blood clotting time and adjust medication dosages as needed. The PT assay is also used to detect abnormal bleeding and clotting conditions caused by various diseases and disorders, making it a versatile tool in clinical settings.
In addition to the PT assay, the activated partial thromboplastin time (aPTT) test is crucial for assessing the intrinsic system and common pathway of clot formation. This test is primarily used to monitor heparin therapy in post-surgical hospital patients. Other important tests include the antithrombin III test, bleeding time test, and clot retraction test, each providing valuable information for diagnosing and managing bleeding disorders.
Looking ahead to 2029, coagulation testing procedures will continue to be vital for diagnosing and managing bleeding disorders and evaluating the effectiveness of blood-related therapies. With ongoing advancements in technology and increasing demand for accurate and efficient testing, Kalorama Information forecasts that the future of coagulation testing looks promising. As the market continues to grow, healthcare providers and laboratories will benefit from the enhanced capabilities and improved outcomes offered by these advanced diagnostic tools.
For more information, purchase IVD Test Procedure Volumes, 2024-2029.
About the Report
Unlock key insights into the future of in vitro diagnostics with Kalorama Information’s IVD Test Procedure Volumes, 2024-2029 report. This indispensable resource dives deep into global IVD procedural trends, offering valuable data on the rapidly evolving landscape. As a companion to Kalorama’s acclaimed market analysis, The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 17th Edition, this report equips you with the tools to:
- Strategize for Success: Gain forward-looking perspectives on how product innovations, cost pressures, and shifting disease profiles will shape the IVD industry through 2029.
- Master Market Dynamics: Access detailed insights into procedure volumes across regions, test types, and market segments, from point-of-care and clinical chemistry to hematology.
- Capitalize on Emerging Opportunities: Identify high-growth areas while navigating the challenges posed by evolving healthcare demands and regulatory changes.